The publication examines the Transferable Data Exclusivity Voucher (TDEV) as one of the most innovative elements of the proposed reform of European pharmaceutical legislation. The new instrument is designed to incentivize the development of urgently needed novel antimicrobials by granting successful developers a transferable voucher that extends the regulatory data exclusivity of a medicinal product by twelve months. The voucher may be transferred once to another company and used for a different centrally authorized medicinal product.<\/p>\n\n\n\n
The article outlines the requirements for obtaining the voucher and explains the safeguards introduced during the legislative process, including strict eligibility criteria, revenue thresholds, transparency obligations, and limits on transferability. These measures are intended to encourage pharmaceutical innovation while preventing an excessive extension of exclusivity rights that could hinder competition.<\/p>\n\n\n\n
The authors conclude that the TDEV represents a promising but still unproven regulatory approach. Whether the instrument will effectively stimulate greater investment in antimicrobial research remains to be seen. Its long-term success will depend on striking the right balance between fostering innovation and limiting the impact on competition and healthcare systems.<\/p>\n\n\n\n